...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Phenyl N-tert-Butylnitrone Down-Regulates Interleukin-1beta-Stimulated Matrix Metalloproteinase-13 Gene Expression in Human Chondrocytes: Suppression of c-Jun NH_2-Terminal Kinase, p38-Mitogen-Activated Protein Kinase and Activating Protein-1
【24h】

Phenyl N-tert-Butylnitrone Down-Regulates Interleukin-1beta-Stimulated Matrix Metalloproteinase-13 Gene Expression in Human Chondrocytes: Suppression of c-Jun NH_2-Terminal Kinase, p38-Mitogen-Activated Protein Kinase and Activating Protein-1

机译:苯基N-叔丁基硝酮下调人软骨细胞中白介素1β刺激的基质金属蛋白酶-13基因表达:c-Jun NH_2终端激酶,p38丝裂原活化蛋白激酶和激活蛋白1的抑制。

获取原文
获取原文并翻译 | 示例

摘要

Cytokine-mediated induction and overexpression of matrix metalloproteinases (MMPs) is recognized as an important factor in the pathogenesis of arthritis. Interleukin (IL)-1beta is a proinflammatory cytokine that is known to superinduce the expression and production of MMP-13 in many cell types. Phenyl N-tert-butylnitrone (PBN), a spin trap agent, inhibited the IL-1beta-induced expression of MMP-13 in human osteoarthritis (OA) chondrocytes. Down regulation of MMP-13 expression correlated with the inhibition of mitogen-activated protein kinase (MPK) subgroups c-Jun NH_2-terminal kinase (JNK) and p38-MAPK activation, accumulation of phospho-c-jun, and the DAN binding activity of activating protein-1 (AP-1). Results of in vitro kinase assays showed that exogenously added PBN completely blocked the c-Jun phosphorylating activity of JNK. Interestingly, using in vitro kinase assay, we also found that chondrocyte p38-MAPK phosphorylate c-Jun and that PBN was not very effective in inhibiting c-Jun phosphorylating activity of P38-MAPK. In addition, PBN did not block the ATF-2 phosphorylating activity of p38-MAPK and Elk-1 phosphorylating activity of extracellular regulated kinase p44/p42 in vitro, indicating that PBN may act selectively to inhibit the phosphorylation of c-Jun in OA chondrocytes. Together, our results for the first time demonstrate that PBN suppress the IL-1beta-stimulated expression of MMP-13 in OA chondrocytes and that this was achieved by inhibiting the activation of JNK and AP-1. These results suggest that use of PBN or compounds derived from it may be of potential benefit in inhibiting signaling events associated with cartilage degradation in arthritis.
机译:细胞因子介导的基质金属蛋白酶(MMPs)的诱导和过表达被认为是关节炎发病机制中的重要因素。白介素(IL)-1beta是一种促炎细胞因子,已知可以在许多细胞类型中诱导MMP-13的表达和产生。苯基N-叔丁基硝酮(PBN),一种自旋捕集剂,可抑制IL-1β诱导的人骨关节炎(OA)软骨细胞中MMP-13的表达。 MMP-13表达的下调与抑制丝裂原活化蛋白激酶(MPK)亚组c-Jun NH_2-末端激酶(JNK)和p38-MAPK激活,磷酸化c-jun积累和DAN结合活性有关活化蛋白1(AP-1)的作用。体外激酶测定的结果表明,外源添加的PBN完全阻断了JNK的c-Jun磷酸化活性。有趣的是,使用体外激酶测定法,我们还发现软骨细胞p38-MAPK磷酸化c-Jun,而PBN在抑制P38-MAPK的c-Jun磷酸化活性方面不是很有效。此外,PBN在体外没有阻断p38-MAPK的ATF-2磷酸化活性和细胞外调节激酶p44 / p42的Elk-1磷酸化活性,表明PBN可能选择性地抑制OA软骨细胞中c-Jun的磷酸化。 。在一起,我们的结果首次证明PBN抑制OA软骨细胞中IL-1β刺激的MMP-13表达,并且这是通过抑制JNK和AP-1的激活来实现的。这些结果表明,使用PBN或衍生自PBN的化合物在抑制与关节炎中的软骨降解有关的信号传递事件方面可能具有潜在的好处。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号